Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

Figure 1 Time to progression in the chemotherapeutic agent irinotecan, gemcitabine and doxorubicin groups. A: There was a significant difference in time to progression among the three groups (P = 0.018). B: Time to progression in intermediate-stage HCC among the three groups (P = 0.373). HCC: Hepatocellular carcinoma; CPT-11: Chemotherapeutic agent irinotecan; GEM: Gemcitabine; BCLC: Barcelona Clinic Liver Cancer Group.

Figure 2 Overall survival rates in the chemotherapeutic agent irinotecan, gemcitabine and doxorubicin groups. A: Significantly better overall survival rates were observed in the chemotherapeutic agent irinotecan (CPT-11) group than in the GEM and doxorubicin group (P = 0.004). B: Overall survival rates in intermediate-stage HCC among the three groups (P = 0.003). GEM: Gemcitabine; HCC: Hepatocellular carcinoma.